Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

NovaBay Releases Aganocide Information

May 6, 2011 10:48 am | News | Comments

NovaBay Pharmaceuticals, Inc. presented data on three new compounds, NVC-727, NVC-638, and NVC-704. Similar to its lead anti-infective Aganocide compound, NVC-422, these are broad-spectrum, fast-acting antimicrobial agents .

TOPICS:

Pfizer Returns Asthma Drug to Rigel

May 6, 2011 10:41 am | News | Comments

Rigel Pharmaceuticals Inc. said it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials.

TOPICS:

Abbott Stent Earns Expanded Use

May 6, 2011 10:39 am | News | Comments

Federal health officials have expanded approval of an artery-opening stent from Abbott to a larger group of patients at risk for stroke caused by plaque buildup in the neck arteries.

TOPICS:
Advertisement

FDA Clears MRSA Diagnostic

May 6, 2011 10:37 am | News | Comments

The U.S. Food and Drug Administration cleared the first test for Staphylococcus aureus infections that is able to quickly identify whether the bacteria are methicillin resistant (MRSA) or methicillin susceptible (MSSA).

TOPICS:

Normal Stem Cells Given Cancer Stem Cell Treatment

May 6, 2011 10:34 am | News | Comments

Researchers have isolated normal stem cells that form the developing placenta and given them the same properties of stem cells associated with an aggressive type of breast cancer.

TOPICS:

Drug-resistance Fears for Deadly Fungus

May 6, 2011 10:31 am | News | Comments

Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.

TOPICS:

Pozen Loss Widens to $5.7M

May 6, 2011 10:29 am | News | Comments

Pozen Inc. reported a wider first-quarter loss on a mix of lower revenues, higher costs, and difficult comparisons to the year before, when the drug developer benefited from a huge payment for an arthritis drug.

TOPICS:

Dusa Sales, Revenue Up in 2Q

May 6, 2011 10:27 am | News | Comments

Dusa Pharmaceuticals Inc. reported a loss of $605,000 in the first quarter, compared with $425,000 a year ago. Its per-share loss was unchanged 2 cents. Total revenue rose 27 percent, to $11.1 million from $8.7 million.

TOPICS:
Advertisement

Prexa Pharmaceuticals Hires New Development Team

May 6, 2011 8:29 am | News | Comments

Prexa Pharmaceuticals hired two new candidates for its lead product candidate PRX-12251.

TOPICS:

Antibody Conjugates

May 6, 2011 8:28 am | Drug Discovery & Development | Product Releases | Comments

BioLegend Inc. has released over 50 Brilliant Violet 421 antibody conjugates for use in flow cytometry and microscopy.

TOPICS:

Axcan and Eurand Change Name to Aptalis

May 6, 2011 8:26 am | News | Comments

Axcan Pharma and Eurand announced the renaming of their combined companies to Aptalis Pharma.

TOPICS:

Debiopharm, Yale Collaborate on Debio 1036

May 6, 2011 8:25 am | News | Comments

Debiopharm Group and Yale University announce a worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.

TOPICS:

FDA OKs Novartis' Pancreatic Tumor Drug

May 6, 2011 8:11 am | News | Comments

The U.S. Food and Drug Administration (FDA) approved Novartis' drug Afinitor for treating patients with advanced neuroendocrine tumors originating in the pancreas.

TOPICS:

Millennium: Takeda Oncology Reports on Three VELCADE Studies

May 6, 2011 8:07 am | News | Comments

Millennium: The Takeda Oncology Company reported results from three studies in relapsed multiple myeloma (MM). Two of the studies examined the use of VELCADE (bortezomib) for injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

TOPICS:

ERK Role in B Cell Differentiation Explained

May 6, 2011 7:37 am | News | Comments

In an article in Science Signaling, researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) explained the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading